drugset / Trial / NCT00752726

Effect of Orlistat in Body Composition

NCT00752726

Phase 4 Completed 131 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if a 24 week weight loss program with orlistat 60 mg will produce greater changes in body composition compared to placebo.

Timeline

Start
2008-09
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Orlistat Small molecule 60 mg Oral

Indications